Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PG 2

Drug Profile

PG 2

Alternative Names: Injectable astragalus polysaccharide; PG2; PHN011; PHN012; PHN013; PHN014; PHN015; Polysaccharides of Astragalus membranaceus; XueBao

Latest Information Update: 10 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmagenesis
  • Developer Pharmagenesis; PhytoHealth
  • Class Phytotherapies; Polysaccharides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Fatigue; Leucopenia
  • Phase II Stroke
  • No development reported Idiopathic thrombocytopenic purpura

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2018 PhytoHealth Corporation initiates a phase II trial for Fatigue (Cancer related) in Taiwan (NCT03314805)
  • 19 Oct 2017 PhytoHealth Corporation plans a phase II trial for Fatigue (Cancer related) in Taiwan (NCT03314805)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top